These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. Wang OH; Azizian N; Guo M; Capello M; Deng D; Zang F; Fry J; Katz MH; Fleming JB; Lee JE; Wolff RA; Hanash S; Wang H; Maitra A PLoS One; 2016; 11(3):e0152300. PubMed ID: 27023625 [TBL] [Abstract][Full Text] [Related]
8. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction. Li Y; Bian Y; Wang K; Wan XP BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301 [TBL] [Abstract][Full Text] [Related]
9. Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation: A Distinctive Pancreatic Carcinoma With Marked Long-Term Survival. Kryklyva V; Ter Linden E; Kroeze LI; de Voer RM; van der Kolk BM; Stommel MWJ; Hermans JJ; Luchini C; Wood LD; Hruban RH; Nagtegaal ID; Ligtenberg MJL; Brosens LAA Pancreas; 2020 Aug; 49(7):999-1003. PubMed ID: 32658072 [TBL] [Abstract][Full Text] [Related]
10. Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis. Espinosa I; Lee CH; D'Angelo E; Palacios J; Prat J Am J Surg Pathol; 2017 Aug; 41(8):1121-1128. PubMed ID: 28498284 [TBL] [Abstract][Full Text] [Related]
11. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425 [TBL] [Abstract][Full Text] [Related]
12. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454 [TBL] [Abstract][Full Text] [Related]
13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
14. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation. Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678 [TBL] [Abstract][Full Text] [Related]
15. PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer. Yi Q; Dong F; Lin L; Liu Q; Chen S; Gao F; He Q Tumour Biol; 2016 May; 37(5):5805-10. PubMed ID: 26546433 [TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708 [TBL] [Abstract][Full Text] [Related]
17. Characterization of hotspot exonuclease domain mutations in the DNA polymerase ϵ gene in endometrial cancer. Tian W; Ji Z; Wang J; Meng J; Bi R; Ren Y; Shan B; Yang G; Wang H Front Oncol; 2022; 12():1018034. PubMed ID: 36313640 [TBL] [Abstract][Full Text] [Related]
18. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532 [TBL] [Abstract][Full Text] [Related]
19. Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. Davila JI; Chanana P; Sarangi V; Fogarty ZC; Weroha SJ; Guo R; Goode EL; Huang Y; Wang C BMC Med Genomics; 2021 Jun; 14(1):165. PubMed ID: 34158040 [TBL] [Abstract][Full Text] [Related]
20. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]